IN OVO CARCINOGENICITY ASSAY (IOCA)

目前，对物质的致癌性测试是通过昂贵的生物分析来评估的，这些生物分析是在为期两年的研究中利用啮齿动物进行的。该项目的目的是开发一种可替代的测定方法，用于禽类胚胎，作为致癌性的筛选试验。卵内致癌性试验（IOCA），在受精卵中进行，解决了动物试验的三个R（减少，改进和替代）。与啮齿动物生物测定相比，IOCA具有许多优势，包括：1)它是一个快速的测试，最多需要24天的时间来完成；2)测试不需要使用任何哺乳动物；3)对鸡蛋进行检测，鸡蛋存放在孵化器中，所需的空间和设备比动物设施少；4)剂量量小，减少了人类接触潜在致癌物的机会；5)与传统的致癌性检测相比，分析成本大大降低。我们建议通过测试已知的致癌物，并将结果与两年的啮齿动物生物测定结果进行比较，来证明IOCA作为一种替代致癌性测定方法的实用性。通过展示IOCA识别致癌物质的预测性和敏感性，我们将建立IOCA作为商业上可行技术的可行性。建议的商业应用：MB研究公司将为制药、生物技术、化妆品、化学和消费品行业提供IOCA。我们目前为客户进行标准的啮齿动物生物测定和加速啮齿动物致癌研究，以及一些基于鸡蛋的研究。一项对我们客户的调查表明，他们需要一种能够快速、廉价地筛查潜在致癌物质的替代检测方法。因此，我们有独特的定位来满足这个行业的需求，并可以向接受的客户群提供这种技术，占据测试市场的重要部分。

Carcinogenicity testing of substances is currently assessed via costly bioassays utilizing rodents in two year studies. The objective of this project is to develop an alternative assay which is performed on avian embryos as a screening test for carcinogenicity. The in ovo carcinogenicity assay (IOCA), conducted in fertilized turkey eggs, which addresses the three R's (reduction, refinement and replacement) of animal testing. The IOCA has numerous advantages over the rodent bioassay, including: 1) it is a rapid test, requiring a maximum of 24 days to perform; 2) testing does not require use of any mammals; 3) testing is performed on eggs, which are kept in incubators, requiring less space and equipment than animal facilities; 4) dose amounts are small, which reduces exposure of humans to potential carcinogens; and 5) cost of analysis is greatly reduced when compared to traditional carcinogenicity testing. We propose to demonstrate the utility of the IOCA as an alternative carcinogenicity assay by testing known carcinogens and comparing the results to those from two year rodent bioassays. By demonstrating the predictivity and sensitivity of IOCA to identify carcinogenic substances, we will establish the feasibility of IOCA as a commercially viable technology. PROPOSED COMMERCIAL APPLICATIONS: MB Research will offer the IOCA to the pharmaceutical, biotech, cosmetic, chemical and consumer products industries. We currently perform standard rodent bioassays and accelerated rodent carcinogenesis studies, as well as several egg-based studies for our clients. A survey of our clients indicates a demand for an alternative test that allows for rapid, inexpensive screening of potential carcinogenic substances. Thus, we are uniquely positioned to fulfill this industry demand and can provide this technology to a receptive client base, capturing a significant portion of the testing market.